(Total Views: 415)
Posted On: 07/21/2020 10:02:13 AM
Post# of 302
re: The HDC Shareholders letter back on 12/06/19
At the bottom of the second page as follows...........
With regard to future development opportunities, we have been in discussions to identify areas of collaboration with a medical and bioinformatics research institution. The specific areas under discussion include image processing and analysis, flow cytometry, cytogenetics, uses of SVM-RFE in medical research and prostate cancer. If successful, this collaboration could help open new areas of commercial development for our Company. Although these discussions are highly promising and continuing, we cannot be sure of success.
____________________________
I would like to know what medical institute and why haven't they been successful?
So why can't HDC identify the so called medical BIO institute?
At the bottom of the second page as follows...........
With regard to future development opportunities, we have been in discussions to identify areas of collaboration with a medical and bioinformatics research institution. The specific areas under discussion include image processing and analysis, flow cytometry, cytogenetics, uses of SVM-RFE in medical research and prostate cancer. If successful, this collaboration could help open new areas of commercial development for our Company. Although these discussions are highly promising and continuing, we cannot be sure of success.
____________________________
I would like to know what medical institute and why haven't they been successful?
So why can't HDC identify the so called medical BIO institute?
(0)
(0)
